Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Saeed Taheri, Mohammad Ali Sahraian & Nazila Yousefi. (2019) Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Journal of Medical Economics 22:1, pages 71-84.
Read now
Read now
Evan W Davies, Samuel Llewellyn, Amélie Beaudet, Charlotte E Kosmas, Wendy Gin-Sing & Helen A Doll. (2018) Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Preference and Adherence 12, pages 1079-1088.
Read now
Read now
Julian Nam, Robert Milenkovski, Simon Yunger, Marc Geirnaert, Kristjan Paulson & Matthew Seftel. (2018) Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. Journal of Medical Economics 21:1, pages 47-59.
Read now
Read now
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
Articles from other publishers (12)
Christopher Parker, Fei Fei Liu, Kristen A. Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J. Keating & Sonja Sorensen. (2023) Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. Advances in Therapy 40:5, pages 2355-2374.
Crossref
Crossref
Nihar R. Desai, Caresse Campbell, Batul Electricwala, Margaret Petrou, David Trueman, Fionn Woodcock & Joaquim Cristino. (2022) Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. American Journal of Cardiovascular Drugs 22:5, pages 545-556.
Crossref
Crossref
Louis S. Matza, Katie D. Stewart, Andrew J. Lloyd, Donna Rowen & John E. Brazier. (2021) Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. Value in Health 24:6, pages 812-821.
Crossref
Crossref
Wei-Han Cheng, Étienne Gaudette & Dana P. Goldman. (2017) PCSK9 Inhibitors Show Value for Patients and the US Health Care System. Value in Health 20:10, pages 1270-1278.
Crossref
Crossref
K. Steen Carlsson, E. Andersson & E. Berntorp. (2017) Preference-based valuation of treatment attributes in haemophilia A using web survey. Haemophilia 23:6, pages 894-903.
Crossref
Crossref
Jean-Jacques Body, Francesca Gatta, Erwin De Cock, Sunning Tao, Persefoni Kritikou, Pauline Wimberger, Jeroen Mebis, Marc Peeters, Paolo Pedrazzoli, Augusto Caraceni, Vincenzo Adamo & Guy Hechmati. (2017) An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Supportive Care in Cancer 25:9, pages 2823-2832.
Crossref
Crossref
Louis S. Matza, Katie D. Stewart, Evan W. Davies, Richard Hellmund, William H. Polonsky & David Kerr. (2017) Health State Utilities Associated with Glucose Monitoring Devices. Value in Health 20:3, pages 507-511.
Crossref
Crossref
Sara Olofsson, Hanna Norrlid, Eva Karlsson, Ulla Wilking & Gunnel Ragnarson Tennvall. (2016) Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting. The Breast 29, pages 140-146.
Crossref
Crossref
Evan W. Davies, Louis S. Matza, Gavin Worth, David H. Feeny, Jacqueline Kostelec, Steven Soroka, David Mendelssohn, Philip McFarlane & Vasily Belozeroff. (2015) Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes 13:1.
Crossref
Crossref
Louis S. Matza, Sandhya J. Sapra, John F. Dillon, Anupama Kalsekar, Evan W. Davies, Mary K. Devine, Jessica B. Jordan, Amanda S. Landrian & David H. Feeny. (2014) Health state utilities associated with attributes of treatments for hepatitis C. The European Journal of Health Economics 16:9, pages 1005-1018.
Crossref
Crossref
Kelly L. Stoner, Helena Harder, Lesley J. Fallowfield & Valerie A. Jenkins. (2014) Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. The Patient - Patient-Centered Outcomes Research 8:2, pages 145-153.
Crossref
Crossref
Rohini K. Hernandez, Jane Quigley, Melissa Pirolli, David Quach, Kristina S. Chen, Jorge Arellano & Alexander Liede. (2014) Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Supportive Care in Cancer 22:10, pages 2697-2705.
Crossref
Crossref